Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on LinkedIn:
“Top Breast Cancer Data from ESMO25
This year’s congress delivered a wave of practice-changing updates across both early and metastatic breast cancer.
Thirteen key Late-Breaking Abstracts (LBAs) and orals stood out:
Early Breast Cancer
- DESTINY-Breast11 (291O) – Neoadjuvant T-DXd ± THP vs SOC
- DESTINY-Breast05 (LBA1) – T-DXd vs T-DM1 in residual HER2+ EBC
- POSITIVE (LBA12) – 5-year follow-up on pregnancy outcomes
- monarchE (LBA13) – OS results with adjuvant abemaciclib
- NATALEE (LBA14) – 5-year outcomes of adjuvant ribociclib
- Pembrolizumab low-dose TNBC (LBA15) – chemo-IO neoadjuvant
Metastatic Breast Cancer
- VIKTORIA-1 (LBA17) – Gedatolisib + fulvestrant ± palbociclib DESTINY-Breast09
- (LBA18) – T-DXd + pertuzumab vs THP HORIZON-Breast01
- (LBA19) – SHR-A1811 vs pyrotinib/capecitabine ASCENT-03
- (LBA20) – SG vs chemo in untreated TNBC (PD-L1–) OptiTROP-Breast02
- (LBA23) – Sacituzumab tirumotecan vs chemo Trastuzumab botidotin
- (LBA24) – vs T-DM1 in HER2+ MBC
- CULMINATE-2 (LBA25) – Culmerciclib + fulvestrant 1L HR+/HER2–
These data will influence how we treat HER2+, HR+/HER2–, and TNBC patients across the disease spectrum — from young women considering pregnancy, to patients with heavily pre-treated metastatic disease.”
More posts featuring Amol Akhade.